-
Je něco špatně v tomto záznamu ?
Lycorine and homolycorine derivatives for chemo-sensitizing resistant human ovarian adenocarcinoma cells
SAR. Sancha, S. Dobiasová, T. Nejedlý, O. Strnad, J. Viktorová, MU. Ferreira
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
- MeSH
- adenokarcinom * MeSH
- alkaloidy amarylkovitých * farmakologie MeSH
- alkaloidy * farmakologie MeSH
- chemorezistence MeSH
- doxorubicin farmakologie MeSH
- fenantridiny * MeSH
- karbamáty farmakologie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- P-glykoprotein metabolismus MeSH
- P-glykoproteiny metabolismus MeSH
- protinádorové látky * farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Multidrug resistance is the major obstacle to cancer chemotherapy. Modulation of P-glycoprotein and drug combination approaches have been considered important strategies to overcome drug resistance. PURPOSE: Aiming at generating a small library of Amaryllidaceae-type alkaloids to overcome drug resistance, two major alkaloids, isolated from Pancratium maritimum, lycorine (1), and 2α-10bα-dihydroxy-9-O-demethylhomolycorine (2), were derivatized, giving rise to nineteen derivatives (3 - 21). METHODS: The main chemical transformation of lycorine resulted from the cleavage of ring E of the diacetylated lycorine derivative (3) to obtain compounds that have carbamate and amine functions (5 - 16), while acylation of compound 2 provided derivatives 17 - 21. Compounds 1 - 21 were evaluated for their effects on cytotoxicity, and drug resistance reversal, using resistant human ovarian carcinoma cells (HOC/ADR), overexpressing P-glycoprotein (P-gp/ABCB1), as model. RESULTS: Excluding lycorine (1) (IC50 values of 1.2- 2.5 μM), the compounds were not cytotoxic or showed moderate/weak cytotoxicity. Chemo-sensitization assays were performed by studying the in vitro interaction between the compounds and the anticancer drug doxorubicin. Most of the compounds have shown synergistic interactions with doxorubicin. Compounds 5, 6, 9 - 14, bearing both carbamate and aromatic amine moieties, were found to have the highest sensitization rate, reducing the dose of doxorubicin 5-35 times, highlighting their potential to reverse drug resistance in combination chemotherapy. Selected compounds (4 - 6, 9 - 14, and 21), able of re-sensitizing resistant cancer cells, were further evaluated as P-gp inhibitors. Compound 11, which has a para‐methoxy-N-methylbenzylamine moiety, was the strongest inhibitor. In the ATPase assay, compounds 9-11 and 13 behaved as verapamil, suggesting competitive inhibition of P-gp. At the same time, none of these compounds affected P-gp expression at the mRNA or protein level. CONCLUSIONS: This study provided evidence of the potential of Amaryllidaceae alkaloids as lead candidates for the development of MDR reversal agents.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006538
- 003
- CZ-PrNML
- 005
- 20241009142656.0
- 007
- ta
- 008
- 240412e20240216gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.phymed.2024.155460 $2 doi
- 035 __
- $a (PubMed)38394731
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Sancha, Shirley A R $u Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
- 245 10
- $a Lycorine and homolycorine derivatives for chemo-sensitizing resistant human ovarian adenocarcinoma cells / $c SAR. Sancha, S. Dobiasová, T. Nejedlý, O. Strnad, J. Viktorová, MU. Ferreira
- 520 9_
- $a BACKGROUND: Multidrug resistance is the major obstacle to cancer chemotherapy. Modulation of P-glycoprotein and drug combination approaches have been considered important strategies to overcome drug resistance. PURPOSE: Aiming at generating a small library of Amaryllidaceae-type alkaloids to overcome drug resistance, two major alkaloids, isolated from Pancratium maritimum, lycorine (1), and 2α-10bα-dihydroxy-9-O-demethylhomolycorine (2), were derivatized, giving rise to nineteen derivatives (3 - 21). METHODS: The main chemical transformation of lycorine resulted from the cleavage of ring E of the diacetylated lycorine derivative (3) to obtain compounds that have carbamate and amine functions (5 - 16), while acylation of compound 2 provided derivatives 17 - 21. Compounds 1 - 21 were evaluated for their effects on cytotoxicity, and drug resistance reversal, using resistant human ovarian carcinoma cells (HOC/ADR), overexpressing P-glycoprotein (P-gp/ABCB1), as model. RESULTS: Excluding lycorine (1) (IC50 values of 1.2- 2.5 μM), the compounds were not cytotoxic or showed moderate/weak cytotoxicity. Chemo-sensitization assays were performed by studying the in vitro interaction between the compounds and the anticancer drug doxorubicin. Most of the compounds have shown synergistic interactions with doxorubicin. Compounds 5, 6, 9 - 14, bearing both carbamate and aromatic amine moieties, were found to have the highest sensitization rate, reducing the dose of doxorubicin 5-35 times, highlighting their potential to reverse drug resistance in combination chemotherapy. Selected compounds (4 - 6, 9 - 14, and 21), able of re-sensitizing resistant cancer cells, were further evaluated as P-gp inhibitors. Compound 11, which has a para‐methoxy-N-methylbenzylamine moiety, was the strongest inhibitor. In the ATPase assay, compounds 9-11 and 13 behaved as verapamil, suggesting competitive inhibition of P-gp. At the same time, none of these compounds affected P-gp expression at the mRNA or protein level. CONCLUSIONS: This study provided evidence of the potential of Amaryllidaceae alkaloids as lead candidates for the development of MDR reversal agents.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a alkaloidy amarylkovitých $x farmakologie $7 D047151
- 650 _2
- $a chemorezistence $7 D019008
- 650 12
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a doxorubicin $x farmakologie $7 D004317
- 650 _2
- $a P-glykoprotein $x metabolismus $7 D020168
- 650 _2
- $a P-glykoproteiny $x metabolismus $7 D018435
- 650 12
- $a alkaloidy $x farmakologie $7 D000470
- 650 12
- $a adenokarcinom $7 D000230
- 650 _2
- $a karbamáty $x farmakologie $7 D002219
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a fenantridiny $7 D010617
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dobiasová, Simona $u Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, CZ 166 28 Prague, Czech Republic
- 700 1_
- $a Nejedlý, Tomáš $u Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, CZ 166 28 Prague, Czech Republic
- 700 1_
- $a Strnad, Ondřej $u Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, CZ 166 28 Prague, Czech Republic $7 xx0323502
- 700 1_
- $a Viktorová, Jitka $u Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, CZ 166 28 Prague, Czech Republic
- 700 1_
- $a Ferreira, Maria-José U $u Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal. Electronic address: mjuferreira@ff.ulisboa.pt
- 773 0_
- $w MED00003830 $t Phytomedicine $x 1618-095X $g Roč. 126 (20240216), s. 155460
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38394731 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20241009142651 $b ABA008
- 999 __
- $a ok $b bmc $g 2080871 $s 1216305
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 126 $c - $d 155460 $e 20240216 $i 1618-095X $m Phytomedicine $n Phytomedicine $x MED00003830
- LZP __
- $a Pubmed-20240412